Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

SCNI

Scinai Immunotherapeutics Ltd ADR

Nov 12 • 12:49PM ET

1.11

+0.01 0.91 %

Healthcare • Biotechnology • Israel • NASD

Peers: BNTX MRNA REGN AMGN PFE JNJ NVAX VRTX GILD BMY

| Held by: SPDW

Scroll to Statements

Index	-	P/E	0.23	EPS (ttm)	4.91	Insider Own	2.25%	Shs Outstand	0.85M	Perf Week	-4.31%
Market Cap	0.94M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	0.83M	Perf Month	-18.98%
Enterprise Value	7.67M	PEG	-	EPS next Q	-	Inst Own	9.65%	Short Float	6.45%	Perf Quarter	-39.01%
Income	4.06M	P/S	0.82	EPS this Y	-	Inst Trans	-4.04%	Short Ratio	0.33	Perf Half Y	-58.89%
Sales	1.15M	P/B	0.22	EPS next Y	-	ROA	24.20%	Short Interest	0.05M	Perf YTD	-66.82%
Book/sh	5.10	P/C	0.95	EPS next 5Y	-	ROE	138.38%	52W High	6.18 -82.04%	Perf Year	-66.96%
Cash/sh	1.16	P/FCF	-	EPS past 3/5Y	- -	ROIC	34.87%	52W Low	1.00 11.00%	Perf 3Y	-98.66%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-194.42%	Volatility	7.52% 8.55%	Perf 5Y	-99.60%
Dividend TTM	-	EV/Sales	6.67	EPS Y/Y TTM	189.00%	Oper. Margin	-559.36%	ATR (14)	0.11	Perf 10Y	-99.74%
Dividend Ex-Date	-	Quick Ratio	1.32	Sales Y/Y TTM	306.41%	Profit Margin	352.93%	RSI (14)	37.53	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.32	EPS Q/Q	-35.12%	SMA20	-15.53%	Beta	1.67	Target Price	700.00
Payout	0.00%	Debt/Eq	0.21	Sales Q/Q	-32.54%	SMA50	-20.49%	Rel Volume	0.38	Prev Close	1.10
Employees	31	LT Debt/Eq	0.17	Earnings	-	SMA200	-51.17%	Avg Volume	162.37K	Price	1.11
IPO	May 12, 2015	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	34,373	Change	0.91%

Oct-06-25 07:30AM	Scinai Awarded Israel Innovation Authority Grant to Expand Fill-and-Finish CDMO Capabilities (PR Newswire)
Sep-02-25 07:30AM	Scinai Reports Six-Month 2025 Financial Results Highlighting Continued CDMO Revenue Growth and Strengthened Balance Sheet (PR Newswire)
Jul-29-25 07:15AM	Scinai Announces New Peer-Reviewed Publication Supporting PC111 as a Disease-Modifying Therapy for Pemphigus and SJS/TEN (PR Newswire)
Jun-26-25 07:37AM	Scinai Highlights Award-Winning Science Behind PC111 as Key Pincell Researcher Receives "Oscar of Italian Dermatology" (PR Newswire)
Jun-12-25 08:00AM	Scinai Highlights New Funding and CDMO Growth Ahead of BIO International Convention 2025 (PR Newswire)
09:00AM	Loading…
Jun-05-25 09:00AM	Scinai Immunotherapeutics Receives Italian Government Clearance Under Golden Power Regulation for Potential Acquisition of Pincell S.r.l. (PR Newswire) +28.97%
May-30-25 07:00AM	Scinai Reports Q1 2025 Financial Results Highlighting Strong CDMO Revenue Momentum and Reduced Cash Burn (PR Newswire)
May-07-25 04:01PM	Scinai Announces Annual Financial Results for 2024 (PR Newswire)
May-01-25 07:00AM	Scinai Immunotherapeutics and Pincell to Host Webinar on a Blockbuster Drug Candidate for Devastating Rare Skin Diseases (PR Newswire)
Mar-27-25 09:25AM	Scinai signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological Conditions (PR Newswire) -14.83%
Mar-17-25 07:00AM	Scinai to Connect with Investors, Showcase its Innovative I&I pipeline and its Boutique cGMP Biologics CDMO during BIO-Europe Spring 2025 (PR Newswire)
Mar-05-25 07:30AM	SCINAI IMMUNOTHERAPEUTICS ANNOUNCES $10 MILLION STANDBY EQUITY PURCHASE AGREEMENT (PR Newswire)
Jan-06-25 07:31AM	Scinai to Connect with Investors and Pharma Leaders at Upcoming Key US Conferences (PR Newswire)
Dec-16-24 09:25AM	Scinai Immunotherapeutics Establishes U.S. Subsidiary for CDMO Business Unit, Scinai Bioservices Inc. (PR Newswire)
Dec-05-24 08:25AM	Prof. Michael Schn, Director of Dermatology and Venereology at the University Medical Center Gttingen, Germany (UMG), Joins Scinai Immunotherapeutics' Scientific Advisory Board (PR Newswire)
08:00AM	Loading…
Nov-27-24 08:00AM	Dr. Jonathan Sadeh, Former Senior Vice President of Immunology RandD at Bristol-Myers Squibb, Joins Scinai Immunotherapeutics' Scientific Advisory Board (PR Newswire)
08:00AM	Dr. Jonathan Sadeh, Former Senior Vice President of Immunology R&D at Bristol-Myers Squibb, Joins Scinai Immunotherapeutics' Scientific Advisory Board (PR Newswire)
Nov-22-24 07:15AM	Scinai Publishes Financial Results and Provides Business Update; Shareholders' Equity up from negative $7.3 million as of June 30, 2024, to positive $10 million (PR Newswire) +17.22%
Oct-31-24 06:59AM	Scinai Leadership to Showcase Company's cGMP Biologics CDMO and Innovative I&I pipeline during BIO-Europe 2024 (PR Newswire)
Sep-16-24 07:00AM	Scinai to Host Online Expert Panel on Plaque Psoriasis Treatment and Intralesional Injections of anti-IL-17A/F VHH Antibodies (PR Newswire)
Sep-09-24 11:12AM	IBN Announces Latest Episode of The BioMedWire Podcast featuring Amir Reichman, CEO of Scinai Immunotherapeutics Ltd. (GlobeNewswire) -7.46%
Aug-29-24 06:31AM	Scinai Regains Full Compliance with Nasdaq Listing Requirements (PR Newswire)
Aug-21-24 08:45AM	Scinai Announces Closing of Loan Restructuring Agreement with European Investment Bank Converting Approximately $29 million of Debt to Preferred Equity and Leaving Debt Balance of $273,000 (PR Newswire)
Aug-20-24 09:30AM	Scinai Announces Entering into $2 Million Private Equity Commitment Agreement with its largest Existing Shareholder (PR Newswire)
Aug-15-24 07:00AM	Scinai Publishes Q2 2024 Financial Results and Provides Business Update; Restructures $29 Million Bank Loan to Equity; On Track to Regain Nasdaq Compliance by August 23 (PR Newswire)
Aug-13-24 07:00AM	Scinai Announces Signing of Loan Restructuring Agreement with European Investment Bank; Converting Approximately $29 million of Debt to Preferred Equity Convertible into 19.5% Common Equity (PR Newswire)
Aug-05-24 06:30AM	7 F-Rated Stocks for Your August 2024 Sell List (InvestorPlace) -6.76%
Jul-23-24 07:00AM	Scinai Immunotherapeutics Announces Positive Regulatory Feedback from the PEI on the path for Phase 1/2a in Plaque Psoriasis with its anti-IL-17 nanoAb (PR Newswire)
Jul-15-24 12:41PM	PLUG Stock Alert: Plug Power Gets Approval for HyVia Acquisition (InvestorPlace) +45.07%
12:22PM	M Stock Plunges 13% as Macy's Calls Off Take-Private Talks (InvestorPlace)
12:04PM	Loading…
12:04PM	Why Is Scinai Immunotherapeutics (SCNI) Stock Up 56% Today? (InvestorPlace)
07:00AM	Scinai Immunotherapeutics Announces promising results in an in-vivo proof-of-concept psoriatic human skin model (PR Newswire)
Jul-08-24 08:14AM	Scinai Immunotherapeutics Announces Receipt of an Updated Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity (PR Newswire)
Jul-03-24 09:32AM	Scinai Immunotherapeutics Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements (PR Newswire)
Jul-02-24 01:52PM	SCNI Stock Earnings: Scinai Immunotherapeutics Reported Results for Q1 2024 (InvestorPlace)
08:12AM	Scinai Publishes Q1 2024 Financial Results and Provides Business Update (PR Newswire)
Jun-21-24 07:52AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace) -8.16%
Jun-17-24 07:56AM	Why Is Scinai Immunotherapeutics (SCNI) Stock Up 88% Today? (InvestorPlace) +60.46%
07:40AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
Jun-13-24 07:00AM	Scinai Immunotherapeutics Announces Receipt of a Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity (PR Newswire)
Jun-07-24 07:00AM	Scinai Immunotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement; Continues to Work with the European Investment Bank to Convert Loan to Equity to Regain Compliance with Nasdaq Minimum Shareholders' Equity Requirement (PR Newswire) -28.41%
Jun-03-24 10:52AM	SCNI Stock Earnings: Scinai Immunotherapeutics Reported Results for Q4 2023 (InvestorPlace) -5.33%
May-24-24 04:01PM	Scinai Immunotherapeutics Announces Receipt of a Nasdaq Staff Determination Letter Regarding Shareholders' Equity listing requirements and Hearing to Present a Plan for Regaining Compliance (PR Newswire) +12.46% -9.42%
May-15-24 04:01PM	Scinai Publishes FY 2023 Financial Statements, Files Annual Report on Form 20-F and Provides Business Update (PR Newswire)
May-06-24 09:21AM	Scinai Immunotherapeutics Announces Receipt of Nasdaq Delisting Notification and Appeal (PR Newswire)
Apr-10-24 07:00AM	Scinai to showcase its novel biological local therapeutic for Plaque Psoriasis at Dermatology Drug Development Summit together with Prof. Michael Schn of UMG (PR Newswire)
Apr-08-24 07:00AM	Scinai Immunotherapeutics' CDMO Unit Selected by Ayana Pharma to Provide Drug Development and cGMP Manufacturing Services (PR Newswire)
Mar-12-24 08:00AM	Scinai leadership to attend BIO-Europe Spring 2024 (PR Newswire)
Feb-29-24 08:45AM	Scinai to showcase its cGMP biologics CDMO and innovative NanoAb pipeline at MIXiii 2024 (PR Newswire)
Feb-13-24 07:00AM	Scinai Welcomes Liat Halpert as Head of Business Development and Sales (PR Newswire)
Jan-25-24 10:26AM	Scinai Immunotherapeutics Congratulates its Co-Lead Scientific Research Collaborator Dirk Grlich on Louis-Jeantet Prize (PR Newswire)
Jan-04-24 04:01PM	Scinai Immunotherapeutics Announces Closing of Exercise of Outstanding Warrants for $1.69 Million in Gross Proceeds (PR Newswire) -5.84%
06:15AM	Scinai Immunotherapeutics CEO Issues Letter to Shareholders (PR Newswire)
Dec-29-23 09:21AM	Scinai Immunotherapeutics Announces Exercise of Outstanding Warrants for $1.69 Million in Gross Proceeds (PR Newswire) -14.93%
Dec-27-23 07:15AM	Scinai (NASDAQ: SCNI) to Host Analyst and Investor Webinar on January 9 (PR Newswire) +9.35%
Dec-20-23 08:05AM	Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors (GlobeNewswire)
Dec-12-23 07:26AM	Scinai Announces Promising Results in a Psoriatic Human Skin Model (PR Newswire) -5.71%
Dec-11-23 08:11AM	Study published in Antiviral Research supports promise of Scinai Immunotherapeutics' coronavirus NanoAb as aerosolized prophylactic and therapeutic drug (PR Newswire)
Nov-29-23 09:25AM	European Investment Bank (EIB) extends maturity of its finance facility with Scinai Immunotherapeutics from 2027 to 2031 (PR Newswire) +7.14%
Nov-20-23 07:30AM	Scinai Immunotherapeutics Regains Compliance with Nasdaq's Stockholders' Equity Rule (PR Newswire) -6.35%
Nov-06-23 07:30AM	Scinai Immunotherapeutics Announces Award of Non-Dilutive Grant from Israel Innovation Authority Supporting its New CDMO Business Unit (GlobeNewswire)
Nov-03-23 04:30PM	Scinai Immunotherapeutics Provides Update Regarding Nasdaq Compliance (GlobeNewswire)
Oct-31-23 09:00AM	European Investment Bank (EIB) considering extending maturity of its financial facility contract with Scinai Immunotherapeutics in light of Scinai's recent strategic pivot (GlobeNewswire)
08:23AM	Scinai Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Oct-30-23 07:00AM	Scinai Immunotherapeutics to Attend BIO-Europe Munich 2023 (GlobeNewswire)
Oct-04-23 07:30AM	Scinai Immunotherapeutics to Showcase its end-to-end cGMP Biologics CDMO Services at CPHI Barcelona 2023 (GlobeNewswire) -6.12%
Sep-19-23 04:05PM	Scinai Immunotherapeutics Announces Closing of $1.33 Million Registered Direct Offering (GlobeNewswire)
Sep-15-23 09:01AM	Scinai Immunotherapeutics Announces $1.33 Million Registered Direct Offering (GlobeNewswire) -15.52%
Sep-13-23 04:13PM	Scinai Immunotherapeutics Innovative Plaque Psoriasis Treatment Shows Encouraging Preclinical Results (GlobeNewswire) -11.45%
Sep-11-23 07:30AM	Scinai Immunotherapeutics Ltd. to participate this week in H.C. Wainwright 25th Annual Global Investment Conference in New York and LSX USA Congress 2023 in Boston (GlobeNewswire)
Sep-06-23 06:00AM	BiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd. to Reflect New Focus on Development of Novel Inflammation and Immunology (I&I) Biological Therapeutics (GlobeNewswire)
Aug-11-23 09:00AM	BiondVax Reports Second Quarter Financial Results and Provides Business Update (GlobeNewswire)
Aug-01-23 04:01PM	Nasdaq Grants BiondVax Extension to Regain Compliance with Listing Rules (GlobeNewswire)
Jul-11-23 08:17AM	IBN Announces Latest Episode of The Bell2Bell Podcast featuring Amir Reichman, CEO of BiondVax Pharmaceuticals Ltd. (GlobeNewswire)
Jun-05-23 07:00AM	BiondVax signs exclusive license agreement for development and commercialization of a novel anti-IL-17 antibody for treatment of autoimmune and inflammatory diseases including psoriasis (GlobeNewswire) -10.00%
May-30-23 06:00AM	BVXV: Developing anti-IL-17 NanoAb (Zacks Small Cap Research)
May-15-23 04:45PM	BiondVax Announces First Quarter 2023 Financial Results and Provides Business Update (ACCESSWIRE)
Apr-17-23 04:25PM	BiondVax Files FY 2022 Financial Statements and Annual Report on Form 10-K and Provides Business Update (GlobeNewswire) +20.11% -9.30%
Mar-16-23 01:10PM	BiondVax to Present at BIO-Europe Spring (GlobeNewswire) +7.44%
Mar-06-23 01:31PM	IBN Highlights 'Test. Optimize. Scale.' Episode Featuring BiondVax Pharmaceuticals Ltd. CEO Amir Reichman (NewMediaWire)
Mar-03-23 02:07PM	IBN Announces Test. Optimize. Scale. Interview with BiondVax Pharmaceuticals Ltd. CEO Amir Reichman Discussing De-Risked Development Pipeline and Strategic Partnerships with Premier European Research Institutes (GlobeNewswire)
Feb-02-23 02:15PM	BiondVax Presenting at BIO CEO & Investor Conference (GlobeNewswire)
Jan-23-23 11:50AM	BiondVax Touts Additional Preclinical Data From Inhaled COVID-19 Treatment Candidate (Benzinga)
06:25AM	BiondVaxs Innovative Inhaled Anti-SARS-CoV-2 NanoAb Virtually Prevented Illness When Administered Prophylactically in Preclinical In Vivo Study (GlobeNewswire)
Jan-06-23 07:15AM	BiondVaxs Innovative Inhaled COVID-19 Therapy Virtually Eliminated SARS-COV-2 Virus in Preclinical In Vivo Study (GlobeNewswire) -5.18%
Jan-05-23 07:00AM	BiondVax to Present at Biotech Showcase 2023 (GlobeNewswire) +6.17%
Dec-30-22 07:30AM	BiondVax CEO Issues Letter to Shareholders (GlobeNewswire)
Dec-21-22 11:00AM	Aegis Capital Corp. Acted as Sole Bookrunner on an $8 Million Underwritten Public Offering for BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) (ACCESSWIRE)
Dec-20-22 12:42PM	BiondVax Announces Closing of $8 Million Underwritten Public Offering (GlobeNewswire) -5.09%
Dec-16-22 08:48AM	BiondVax Announces Pricing of $8 Million Underwritten Public Offering (GlobeNewswire) -58.62%
Dec-12-22 07:06AM	BiondVax Regains Nasdaq Compliance (GlobeNewswire)
Dec-08-22 11:05AM	BVXV: Positive Preclinical Results for Inhaled COVID-19 NanoAb (Zacks Small Cap Research)
Dec-06-22 08:30AM	IBN (InvestorBrandNetwork) Coverage Initiated for BiondVax Pharmaceuticals Ltd. (GlobeNewswire)
07:30AM	Professor Dr. Matthias Dobbelstein joins BiondVaxs Scientific Advisory Board (GlobeNewswire)
Nov-30-22 09:15AM	BiondVax announces Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Nov-29-22 07:00AM	BiondVax reports successful results in preclinical in vivo study of its innovative inhaled COVID-19 NanoAb therapy (GlobeNewswire) +7.30%
Nov-21-22 06:00AM	BiondVax CEO to Present at the January 2023 Biotech Showcase in San Francisco (PR Newswire)
Nov-15-22 08:33AM	BiondVax Congratulates Dirk Görlich on $1.4 million WLA Prize in Life Sciences (GlobeNewswire)
Nov-10-22 04:00PM	BiondVax Announces Plan to Implement ADS Ratio Change (GlobeNewswire)
Nov-03-22 11:30AM	BiondVax to present at Recent Advances in Fermentation Technology (RAFT) 14 Conference (PR Newswire)

Scinai Immunotherapeutics Ltd. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunomodulation therapies for infectious diseases. It focuses on the flu vaccine candidate that was designed to provide multi-strain and multi-season protection against seasonal and pandemic influenza. The company was founded by Ronald Babecoff and Rami Epstein on July 21, 2003 and is headquartered in Jerusalem, Israel.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SCNI

Scinai Immunotherapeutics Ltd ADR

Upgrade your FINVIZ experience